Tuning inhibitor susceptibility of human 4-hydroxyphenylpyruvate dioxygenase to rescue tyrosine catabolism in the presence of β-triketones
- 1Vrije Universiteit Brussel
Abstract
Human 4-hydroxyphenylpyruvate dioxygenase (HPD) catalyses a key step in tyrosine degradation via homogentisate in liver and kidney cells. Pharmacological inhibition of HPD with nitisinone (NTBC) is standard treatment for tyrosinemia type 1 (HT1) and alkaptonuria (AKU). Although life-changing, continuous NTBC treatment limits metabolic flexibility and complicates emerging gene- and cell-based therapeutic approaches. Engineering HPD variants that retain catalytic activity during NTBC exposure could facilitate restoration of tyrosine metabolism, yet the molecular determinants of inhibitor tolerance remain poorly understood. Here, we applied Knowledge Gaining Directed Evolution (KnowVolution) to enhance NTBC tolerance while considering enzyme activity, predicted stability, and MHC-II peptide binding. Random mutagenesis, site-saturation mutagenesis, and computational analyses identified beneficial substitutions that improved enzyme activity in the presence of NTBC. These substitutions are predominantly located outside the catalytic cavity, suggesting that NTBC tolerance may involve distal structural effects rather than direct modification of inhibitor-binding residues. Recombination of selected substitutions, guided by activity and computational predictions of stability and MHC-II binding, yielded multi-substitution HPD variants with markedly increased NTBC tolerance. The leading variant, HPD-M8, exhibited up to 40-fold greater NTBC tolerance than wild-type HPD and increased tolerance to structurally related {beta}-triketone inhibitors, without an overall increase in predicted MHC-II binder burden. Computational analyses suggested altered catalytic access-pathway energetics without major perturbation of the conserved catalytic machinery, consistent with a possible contribution of distal substitutions to inhibitor tolerance. Together, these findings provide insight into HPD inhibitor tolerance and establish a foundation for future HT1 and AKU therapeutic strategies.
Related
- Structure of a secreted lancelet carotenoid cleavage dioxygenase (CCD), from an ancestral CCD clade
- A Novel Drp1-Golph2 Tether Mediates Mitochondria-Golgi Spatial Association to Orchestrate Mitochondrial Function and Hepatic Lipid Catabolism Across Vertebrates
- Lysophospholipase PNPLA7 is a critical checkpoint of phosphatidylcholine catabolism and turnover for skeletal muscle homeostasis
- Lysosomal multi-omics reveals altered sphingolipid catabolism associated with lysosomal dysfunction in the aging brain
- The mycotoxin zearalenone couples secondary metabolism to N-acetylglucosamine catabolism
BibTeX
@misc{neuckermans2026tuning,
title = {{Tuning inhibitor susceptibility of human 4-hydroxyphenylpyruvate dioxygenase to rescue tyrosine catabolism in the presence of β-triketones}},
author = {J. Neuckermans and A. Mertens and S. Lequeue and N. S. Salvi and L. Desmet and G. G. Del'Haye and K. Tretowicz and T. Vanhaecke and U. Schwaneberg and J. De Kock},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.760921},
url = {https://www.biorxiv.org/content/10.64898/2026.10.22.760921v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Tuning inhibitor susceptibility of human 4-hydroxyphenylpyruvate dioxygenase to rescue tyrosine catabolism in the presence of β-triketones
AU - J. Neuckermans
AU - A. Mertens
AU - S. Lequeue
AU - N. S. Salvi
AU - L. Desmet
AU - G. G. Del'Haye
AU - K. Tretowicz
AU - T. Vanhaecke
AU - U. Schwaneberg
AU - J. De Kock
PY - 2026
DA - 2026/10/22
PB - bioRxiv
DO - 10.64898/2026.10.22.760921
UR - https://www.biorxiv.org/content/10.64898/2026.10.22.760921v1
AB - Human 4-hydroxyphenylpyruvate dioxygenase (HPD) catalyses a key step in tyrosine degradation via homogentisate in liver and kidney cells. Pharmacological inhibition of HPD with nitisinone (NTBC) is standard treatment for tyrosinemia type 1 (HT1) and alkaptonuria (AKU). Although life-changing, continuous NTBC treatment limits metabolic flexibility and complicates emerging gene- and cell-based therapeutic approaches. Engineering HPD variants that retain catalytic activity during NTBC exposure could facilitate restoration of tyrosine metabolism, yet the molecular determinants of inhibitor tolerance remain poorly understood. Here, we applied Knowledge Gaining Directed Evolution (KnowVolution) to enhance NTBC tolerance while considering enzyme activity, predicted stability, and MHC-II peptide binding. Random mutagenesis, site-saturation mutagenesis, and computational analyses identified beneficial substitutions that improved enzyme activity in the presence of NTBC. These substitutions are predominantly located outside the catalytic cavity, suggesting that NTBC tolerance may involve distal structural effects rather than direct modification of inhibitor-binding residues. Recombination of selected substitutions, guided by activity and computational predictions of stability and MHC-II binding, yielded multi-substitution HPD variants with markedly increased NTBC tolerance. The leading variant, HPD-M8, exhibited up to 40-fold greater NTBC tolerance than wild-type HPD and increased tolerance to structurally related {beta}-triketone inhibitors, without an overall increase in predicted MHC-II binder burden. Computational analyses suggested altered catalytic access-pathway energetics without major perturbation of the conserved catalytic machinery, consistent with a possible contribution of distal substitutions to inhibitor tolerance. Together, these findings provide insight into HPD inhibitor tolerance and establish a foundation for future HT1 and AKU therapeutic strategies.
ER -